STAT3-IN-52
STAT3-IN-52 is an orally active STAT3 inhibitor with a Ki value of 2.42 μM. STAT3-IN-52 binds directly and selectively to the pY705 site of STAT3 (Ki = 0.44 μM), thereby impairing its function. STAT3-IN-52 induces apoptosis and triggers anti-tumor responses in vivo. STAT3-IN-52 can be used in breast cancer-related research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1556861-34-7
- 화학식: C20H20N4O4S
- 분자량:412.46
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
STAT3 2.42 μM (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF S-180 | IC50 |
0.42 μM
Compound: 9
|
Antiproliferative activity against human S180 cells after 24 hrs by MTT assay
Antiproliferative activity against human S180 cells after 24 hrs by MTT assay
|
[PMID: 28245116] |
In Vitro
STAT3-IN-52 (Compound 9) selectively binds to the pY705 site of purified STAT3 protein with a Ki of 0.44 μM, and exhibits no binding activity toward purified STAT1 or STAT5 proteins[1].
STAT3-IN-52 binds directly to fluorescently labeled purified STAT3 protein, with a Ki value of 2.42 μM at a ligand-to-protein molar ratio of 1:1[1].
STAT3-IN-52 (0-400 μM; 24 h) inhibits the viability of human normal mammary epithelial MCF-10A cells, with an IC50 of 128.9 μM, and its potency against normal cells is 184-fold lower than that against MDA-MB-231 cancer cells[1].
STAT3-IN-52 (0.1-10 μM; 24 h) inhibits the viability of human basal-like breast cancer MDA-MB-231 cells, with an IC50 value of 0.7 μM[1].
STAT3-IN-52 (0.1-10 μM; 24 h) inhibits the viability of human medulloblastoma (UW426, UW288-1), human pancreatic cancer (BKPC3), human osteosarcoma (U2OS), and mouse sarcoma (S180) cells, with an IC50 of 0.42 μM against S180 cells[1].
STAT3-IN-52 (5 μM; 0-24 h) time-dependently and selectively inhibits the DNA-binding activity of STAT3 homodimers in human basal-like breast cancer MDA-MB-231 cells, exerts weak effects on STAT1 dimer binding, and does not inhibit IFN-γ-induced STAT1 binding or STAT5 dimer binding[1].
STAT3-IN-52 reduces the mRNA expression of the oncogene MMP9 in human basal-like breast cancer MDA-MB-231 cells, but exerts no significant effect on the expression of the CDK2 gene in these cells[1].
STAT3-IN-52 (2.5-10 μM; 12 h) dose-dependently reduces the level of p-STAT3Y705, inhibits IL-6-induced STAT3 phosphorylation, upregulates SHP-1 expression and induces the production of cleaved caspase-3 in human basal-like breast cancer MDA-MB-231 cells, without affecting other modification sites of STAT3, total STAT3, or the phosphorylation of AKT, ERK1/2 or STAT1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human basal-like breast cancer MDA-MB-231 cells
-
Concentration:2.5, 5 and 10 μM
-
Incubation Time:12 h; 2 h pre-incubation before 30 min IL-6 stimulation
-
Result:Reduced the level of p-STAT3 (Y705) in a dose-dependent manner, without altering levels of acetylated STAT3 (K685), p-STAT3 (S727), total STAT3, p-AKT, or p-ERK1/2.
Inhibited IL-6-induced phosphorylation of STAT3, but did not inhibit p-STAT1 (Y701) or IFN-γ-induced phosphorylation of STAT1.
Increased the expression of SHP-1 and cleaved caspase-3.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-∞ | Vz | CL | MRT0-t | MRT0-∞ | F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 1 mg/kg | i.v. | 0.71 h | 0.033 h | 359.0 ng/mL | 198 ng·h/mL | 199.2 ng·h/mL | 4944.2 mL/kg | 5261.7 mL/h/kg | 0.55 h | 0.71 h | 44.7 % |
| Rat[1] | 10 mg/kg | p.o. | 1.98 h | 0.5 h | 540.3 ng/mL | 850 ng·h/mL | 889 ng·h/mL | 32092.5 mL/kg | 11766.8 mL/h/kg | 1.87 h | 2.25 h | / |
In Vivo
STAT3-IN-52 (5 mg/kg; p.o.; daily; 21 days) orally reduces S180 sarcoma xenograft weight by 73% with minimal systemic toxicity[1].
STAT3-IN-52 (200-1000 mg/kg; i.p.; single dose) exhibits very low acute toxicity in ICR mice, with an estimated therapeutic index of over 100[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (6-week-old female, athymic SPF, subcutaneous xenograft of human MDA-MB-231 breast cancer cells)[1]
-
Dosage:2.5 mg/kg; 5 mg/kg; 10 mg/kg
-
Administration:p.o.; daily; 32 days
-
Result:Reduced tumor weight by 53% at 2.5 mg/kg, 60% at 5 mg/kg, and 70% at 10 mg/kg.
Showed normal body weight gain, with no damage to major organs (heart, liver, spleen, lung, kidney) detected via H&E staining.
Dose-dependently inhibited p-STAT3 (Y705) levels in tumor tissue, with no significant effect on total STAT3 levels, as confirmed by immunohistochemical analysis and Western blot.
-
Animal Model:ICR (4-week-old male, subcutaneous xenograft of mouse S180 sarcoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:p.o.; daily; 21 days
-
Result:Reduced tumor weight by 73% after 21 days of treatment.
Showed normal body weight gain, in contrast to dramatic weight loss observed in doxorubicin-treated mice starting on day 13.
Organs (liver, spleen, kidney) were notably larger than those from doxorubicin-treated mice, indicating less toxicity.
Chemical Information
-
CAS No. 1556861-34-7
-
분자량 412.46
-
화학식 C20H20N4O4S
-
SMILES
O=S(C(C=CC=C1C(C(NC2=CC=CC=C2N3CCNCC3)=C4)=O)=C1C4=O)(N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)